VEGFA and nonpapillary renal cell carcinoma: Hence, anti-VEGF therapies have a noteworthy role in the treatment of advanced ccRCC and have replaced the earlier standard of therapies such as interferon (IFN)-α and interleukin-2 that were in use 2 decades ago [9].